| 1. |
-
- 2019
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
- van der Lee, S. J., et al.
(författare)
-
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
- 2019
-
Ingår i: Acta Neuropathologica. - : Springer Science and Business Media LLC. - 0001-6322 .- 1432-0533. ; 138:2, s. 237-250
-
Tidskriftsartikel (refereegranskat)abstract
- The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenerative diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We replicated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank supported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLC gamma 2 pathway as drug-target.
|
|
| 3. |
|
|
| 4. |
- Gastineau, R., et al.
(författare)
-
Small-scale lobate hillslope features on Mars: A comparative 3D morphological study with terrestrial solifluction lobes and zebra stripe lobes
- 2020
-
Ingår i: Icarus. - : Elsevier BV. - 0019-1035. ; 342
-
Tidskriftsartikel (refereegranskat)abstract
- Small-scale lobes (SSL) observed at the surface of Mars are thought to be the result of solifluction. Hence, their existence has important implications for our understanding of recent climate history, the distribution of thaw liquids and its geomorphic effects, as water is believed not to have been recently stable at the martian surface. These small-scale lobes are limited to sloping terrains and often occur alongside polygonal patterned ground attesting to the presence of ice in the environment. In this study, we perform a comparative 3D morphometric analysis of the lobes on Mars with terrestrial analogues. We use data from High Resolution Imaging Science Experiment (HiRISE) camera in order to create Digital Terrain Models (DTMs) on Mars at 1 m/pix. For the terrestrial analogues, we use DTMs and orthophotos from five periglacial environments with solifluction lobes and from one site with lobate features found in the Atacama Desert. The lobate features in the Atacama Desert are found within features called “zebra stripes”, which are apparently unique to the Atacama and are now generally accepted to be the result of seismic shaking. We show that SSL on Mars overlap morphometrically with terrestrial solifluction lobes, and are less similar to zebra stripe lobes. The majority of martian SSL occur below the angle of repose which demonstrates that a dry fall mechanism cannot be responsible for their formation and that lubrication of the subsurface is required. We found that martian SSL only occur on slopes greater than ~10°, a constraint not observed for terrestrial solifluction lobes nor zebra stripe lobes in Atacama. We hypothesise that this apparent constraint does not result from the lowered gravity on Mars, but instead from differing soil properties and/or thermal regime between Mars and Earth which affects the slope at which creep can initiate. We cannot rule out a role of CO2 sublimation in lobe-formation based on our terrestrial measurements. © 2019 Elsevier Inc.
|
|
| 5. |
- Kappos, Ludwig, et al.
(författare)
-
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- 2018
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 391, s. 1263-1273
-
Tidskriftsartikel (refereegranskat)abstract
- © 2018 Elsevier Ltd Background: No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor 1,5 modulator, on disability progression in patients with SPMS. Methods: This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 hospital clinics and specialised multiple sclerosis centres in 31 countries. Using interactive response technology to assign numbers linked to treatme nt arms, patients (age 18–60 years) with SPMS and an Expanded Disability Status Scale score of 3·0–6·5 were randomly assigned (2:1) to once daily oral siponimod 2 mg or placebo for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression (CDP) events. The primary endpoint was time to 3-month CDP. Efficacy was assessed for the full analysis set (ie, all randomly assigned and treated patients); safety was assessed for the safety set. This trial is registered with ClinicalTrials.gov, number NCT01665144. Findings: 1651 patients were randomly assigned between Feb 5, 2013, and June 2, 2015 (1105 to the siponimod group, and 546 to the placebo group). One patient did not sign the consent form, and five patients did not receive study drug, all of whom were in the siponimod group. 1645 patients were included in the analyses (1099 in the siponimod group and 546 in the placebo). At baseline, the mean time since first multiple sclerosis symptoms was 16·8 years (SD 8·3), and the mean time since conversion to SPMS was 3·8 years (SD 3·5); 1055 (64%) patients had not relapsed in the previous 2 years, and 918 (56%) of 1651 needed walking assistance. 903 (82%) patients receiving siponimod and 424 (78%) patients receiving placebo completed the study. 288 (26%) of 1096 patients receiving siponimod and 173 (32%) of 545 patients receiving placebo had 3-month CDP (hazard ratio 0·79, 95% CI 0·65–0·95; relative risk reduction 21%; p=0·013). Adverse events occurred in 975 (89%) of 1099 patients receiving siponimod versus 445 (82%) of 546 patients receiving placebo; serious adverse events were reported for 197 (18%) patients in the siponimod group versus 83 (15%) patients in the placebo group. Lymphopenia, increased liver transaminase concentration, bradycardia and bradyarrhythmia at treatment initiation, macular oedema, hypertension, varicella zoster reactivation, and convulsions occurred more frequently with siponimod than with placebo. Initial dose titration mitigated cardiac first-dose effects. Frequencies of infections, malignancies, and fatalities did not differ between groups. Interpretation: Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS. Funding: Novartis Pharma AG.
|
|
